Introduction
============

Postoperative pain management is critical during patients\' recovery [@B1]-[@B3]. Nefopam is a clinically effective analgesic agent that is frequently used to control mild to moderate pain [@B4]-[@B6]. The analgesic effect of nefopam involves (i) inhibition of glutamatergic pathway by modulating calcium and sodium channels [@B7], [@B8]; (ii) inhibition of serotonin (5-hydroxytryptamine, 5-HT) and noradrenaline reuptake in the central nervous [@B9], [@B10]. In clinical practice, concomitant use of nefopam and antiemetic agent postoperatively is a possible way to attenuate vomiting which is an adverse effect of nefopam appearing in 15 - 30% of treated patients [@B4].

Ondansetron, a selective serotonin subtype 3 (5-HT~3~) receptors antagonist, is currently used for prophylaxis and treatment of postoperative nausea and vomiting (PONV) in perioperative management [@B11], [@B12]. Some studies have revealed that ondansetron can reduce or block the antinociceptive effect of certain classical analgesics, such as paracetamol [@B13], [@B14] and tramadol [@B15], [@B16], with diverse and unknown mechanisms of action. However, little is known about the effect of ondansetron on the antinociceptive efficacy of nefopam.

Randomized controlled non-inferiority study was carried out to test the hypothesis whether the combination of nefopam and ondansetron would lead to mutually contrasting modifications of serotonergic transmission mediated by 5-HT~3~ receptors, and moreover, whether ondansetron-induced antagonism of 5-HT~3~ receptors could modify the antinociceptive effect of nefopam.

Methods and Materials
=====================

After obtaining the ethic approval from the Ethics Committee of Southwest Hospital, 230 patients (American Society of Anaesthesiologists physical status I or II), whose age were between 30 and 60 years old and scheduled for elective unilateral percutaneous nephrolithotomy (PCNL) surgery, were enrolled in this study. Written informed consent was obtained from each patient. Exclusion criteria were as follows: contraindications for the use of nefopam or ondansetron use; pregnant or lactating women; preoperative use of antiemetic, antidepressant or analgesics; history of motion sickness, epilepsy, or alcohol abuse; severe cardiac disease; renal or hepatic insufficiency. Patients were all unpremedicated.

On the day before surgery, the use of the patient-controlled intravenous analgesia (PCIA) device and of the 100-mm visual analog scale (VAS) (0 mm = no pain, 100 mm = worst imaginable pain) for assessing postoperative pain intensity [@B4] was explained to every patients.

Anaesthesia
-----------

Identical anesthetics and techniques were used for all the patients. General anesthesia was induced intravenously with fentanyl (3μg/kg), midazolam (0.05mg/kg) and propofol (2mg/kg). Then vecuronium (0.1mg/kg) was given to facilitate orotracheal intubation. After endotracheal intubation, general anesthesia was maintained with 1.5 MAC of sevoflurane in 60% nitrous oxide/oxygen; continuous-infusion remifentanil (0.2µg/kg) was used for intraoperative analgesia. Supplementary doses of vecuronium were administered wherever necessary. Mechanical ventilation was adjusted to maintain the end-tidal of PCO~2~ at 4.5∼5.0kPa. Heart rate, non-invasive blood pressure and pulse oximetry were monitored continuously using Marquette Eagle 4000 monitor (GE, New York, USA) throughout the anesthesia and surgery. Ringer\'s solution was infused at 10 ml · kg^-1^ · h^-1^.

At the end of the surgery, inhalational anesthesia was discontinued and a loading dose of nefopam (20mg) was administered to all the patients. Residual neuromuscular blockade was reversed with neostigmine (0.04mg/kg) and atropine (0.02mg/kg) when required. The trachea was extubated when respiration was adequate and the patient responded to verbal commands. All patients were transferred to the postanesthesia care unit (PACU) after extubation.

Postoperative care
------------------

In the PACU, patients were connected to a PCIA device (AutoMed 3300 PCA infusion pump; ACE Medical Company, Kyungi, Korea) and a balloon infuser (Accufuser, 2ml/h; Wooyoung Medical Co., Ltd., Paju, Korea). Using a computerized randomization table, patients were assigned to two groups: Group N (nefopam and saline) or Group O (nefopam and ondansetron). PCIA pumps was filled with nefopam (1.6mg/ml) in saline solution and set with a bolus of 1ml (corresponding with nefopam 1.6mg demand dose), a 10-min lockout interval, a continuous background infusion of 2ml/h, and a 4-hour maximal dose of 30mg. In Group N, the balloon device was filled with 48ml of saline. In Group O, the elastomer contained ondansetron (0.5mg/ml) in saline (total volume, 48ml), with a drug infusion rate of 2ml/h. All drugs and devices were prepared by an anesthetist who was not involved in the management of the patients.

Postoperative pain intensity was evaluated by assessment of pain score on the VAS. Two anesthesiologists, who were blinded with the study protocol, evaluated and recorded the VAS scores at the 0th, 6th, 12th, and 24th hour postoperatively, as well as the respiratory depression, postoperative nausea and vomiting, and the cumulative dose of nefopam consumption during postoperative 24 hours. Any patients who did not obtain satisfactory pain relief from the above PCIA regimen were excluded from further study and then received a single i.v. 50µg dose of fentanyl. For patient with severe nausea and vomiting, an intravenous dose of metoclopramide (generally at 10mg, up to a maximum of 30mg) was administered.

Outcomes
--------

The primary outcome variable was the sum of pain intensity difference (PID) over 24 hours postoperatively (SPID~24hr~) assessed by 0 - 100 mm VAS for the per-protocol population. PID was calculated by subtracting current pain intensity from baseline pain intensity in order to examine the change in pain intensity from the baseline. The SPID~24hr~ for each subject was the sum of the PID at 6 hours (VAS at baseline - VAS at 6 hours), at 12 hours (VAS at baseline - VAS at 12 hours) and at 24 hours (VAS at baseline - VAS at 24 hours). This represented the total reduction in pain intensity over 24 hours.

The secondary outcome variables included: 1) pain intensity assessed through VAS scores at the 0th, 6th, 12th, and 24th hour postoperatively; 2) the cumulative dose of nefopam consumption in postoperative 24 hours; 3) the number of patients requiring rescue medication during postoperative 24 hours; 4) the frequency of adverse events during postoperative 24 hours.

Statistical analysis
--------------------

The primary aim of the study was to show that the combination of nefopam and ondansetron is not inferior to the nefopam alone in term of the treatment of postoperative pain. Based on a standard deviation of 60 mm determined by preliminary experiment and experience, a sample size of 222 patients (111 patients per group) was calculated using NCSS-PASS (NCSS LLC, Kaysville, USA), with a Type I error rate of 0.05. Then our statistical study had 80% power to reject the null hypothesis (nefopam-plus-ondansetron is worse than the nefopam alone) and accept the alternative hypothesis of non-inferiority. 115 patients were included in each group in case there were expulsion cases. Non-inferiority would be declared for nefopam-plus-ondansetron if the lower bound of the two-side 95% confidence interval (CI) of the SPID~24hr~ difference between the two treatment groups was greater than the pre-specified non-inferiority margin (-30mm).

Statistical analysis was performed by SPSS version 17.0 (SPSS Inc, Chicago, Illinois, USA). Data distribution was evaluated with the Shapiro-Wilk\'s test. Parametric data were analyzed by two-tailed independent *t*-test. Nonparametric data were assessed by Wilcoxon signed rank sum test. Category data were analyzed by Chi-square test or Fisher\'s exact test, as appropriate. Values were reported as mean ± SD, absolute number (n), or percentages. A *P*-value \<0.05 was set as statistically significant.

Results
=======

All the 230 patients received their assigned treatments. There were no significant differences between the groups regarding patient demographic characteristics, ASA physical status, duration of surgery, starting time of PICA, and baseline of pain intensity scores (Table [1](#T1){ref-type="table"}).

Postoperative pain was treated successfully in both groups. At the 6th, 12th, 24th hour postoperatively, pain scores were never more than 40 mm according to a VAS. No statistical significant differences were found between the two groups with regard to pain VAS scores at any time point (Fig.[1](#F1){ref-type="fig"}).

SPID~24hr~, the primary outcome variable, was considered as the non-inferiority criterion. The mean SPID~24hr~ score was 95.6 mm in Group N, and 109.3mm in Group O. The SPID~24hr~ difference was the difference between the nefopam-plus-ondansetron and the nefopam alone. The upper and lower limits of the 95% CI of the SPID~24hr~ difference were 24.32 and -14.28 respectively (Table [2](#T2){ref-type="table"}). Clearly, the lower limit of the 95% CI was above the pre-determined non-inferiority margin (-30mm) for SPID~24hr~, which indicated that nefopam-plus-ondansetron is not worse than nefopam alone in relieving the postoperative pain.

In term of the cumulative consumption of nefopam, there was no statistical difference between the two groups (Table [2](#T2){ref-type="table"}). Note that no patient was excluded from the study in both groups as none of them asked for analgesic rescue due to inadequate analgesia.

Postoperative vomiting was significantly more common in Group N (15.7%) compared with that in Group O (3.5%) during the postoperative 24 hours (*P* \< 0.05) (Table [3](#T3){ref-type="table"}). Patients were given significantly more rescue antiemetics in Group N (12.2%) compared with that in Group O (2.6%) (*P* \< 0.05). However, there was no difference in postoperative nausea between the two groups. Incidence of respiratory depression did not occur in patients in both groups.

Discussion
==========

The non-opioid analgesic nefopam is often used for pain management for postoperation patient [@B4], [@B5]. It has been proved that nefopam is effective in different routes of administration [@B17], but to date, its efficacy in PCIA remains unclear. In our study, it is the first time to show that administration of nefopam in PCIA can provide efficacious and safe analgesia to patients after PCNL. Moreover, it is found that there is no antagonistic interaction between ondansetron and nefopam and thus the combination of them is safe to be used to ease pain.

As a minimally invasive surgery, PCNL has been widely accepted. Several new techniques of PCNL, such as mini-PCNL and tubeless PCNL, have been reported to decrease the morbidity and analgesic requirement, but even then it is still a painful procedure. Tangpaitoon and colleagues [@B18] had reported that analog pain score (VAS scores) at the postoperative 1 hour and 4 hour were 68.8 ± 12.7 mm and 50.7 ± 25.8 mm, respectively, for patients who underwent PCNL with general anesthesia. Singh et al. [@B19] had reported that VAS on the first postoperative day morning was 65.6 ± 14.4 mm in the general anesthesia patients. Thus, it is clear that the postoperative administration of analgesic agents is necessary in patients undergoing PCNL.

According to our results, the pain intensity scores were never more than 40 mm referring to a VAS for all of the patients and no rescue analgesic was required. This implies that the postoperative pain can be treated successfully by nefopam in the PCIA route, even if the efficacy of nefopam seems lower than that of opioids [@B17]. The present study provides a possibility to make use of nefopam in PCIA for post-minimally invasive surgery analgesia in clinical practice.

Serotonin plays a key role in pain control mechanisms [@B20] and multiple serotonin receptor subtypes (5-HT~1~, 5-HT~2~ and 5-HT~3~ receptors) are now thought to be involved in the serotonin-mediated antinociceptive mechanism [@B21]. Although the antinociceptive mechanism of action of nefopam is largely unknown, inhibition of the serotonin reuptake in synaptosome and activation of descending serotonergic pathways have been demonstrated [@B6]. A previous animal study has shown that concomitant use of the serotonin depletory *para*-chlorophenylalanine with nefopam completely blocks the analgesic effect of nefopam in the mouse formalin test [@B22]. The authors suggest that the effect of *para*-chlorophenylalanine results from a pharmacodynamic interaction, implying that the central serotonergic pathways may be involved in the mechanism of action of nefopam [@B22]. Nefopam permits endogenous serotonin to exert its antinociceptive effect. Hence, it is theoretically possible that the serotonin receptor antagonists could enhance or weaken the antinociception exerted by nefopam. However, few studies have been performed on the pharmacological interaction between nefopam and serotonin 5-HT~3~ receptor antagonists (dolasetron, granisetron, ondansetron, palonosetron, tropisetron) in human. Moreover, ondansetron is increasingly used for prophylaxis of postoperative nausea and vomiting in perioperative management [@B11], [@B12], whereas tropisetron and granisetron are used only for chemotherapy nausea [@B23]. This is the reason why the interaction between nefopam and ondansetron was assessed in the present study.

Our results indicate that there is no change in the antinociceptive effect of nefopam when ondansetron is co-administered. These findings can be explained as follows: First of all, it has been demonstrated in animal model of pain that ondansetron has little antagonistic effect on the analgesic efficacy of nefopam. Girard and colleagues [@B24] have demonstrated that 5-HT~1B~ and 5-HT~2C~, but not 5-HT~3~, receptor subtypes are involved in the antinociceptive effect of nefopam. These results imply that the serotonergic system implicated in the analgesia exerted by nefopam may involve only specific serotonin receptor subtypes (5-HT~1B~ and 5-HT~2C~) but not all (e.g. 5-HT~3~). Secondly, ondansetron is a substrate of the phosphoglycoprotein (P-gp) transport pump encoded by the MDR1a gene [@B25]. Under normal conditions, ondansetron is actively pumped out of the central nervous system across blood-brain barrier against concentration gradient [@B26]. We consider the possibility that the lack of the change in the antinociceptive effect of nefopam may result from the failure of ondansetron accumulation in the central nervous system to sufficient concentration due to the extrusion by P-gp transport pump. The results in this study suggest that it may be possible to use ondansetron as antiemetics with nefopam during the perioperative period for analgesia.

The higher incidence of vomiting in Group N during the postoperative 24 hours seems to be correlated to the side effects of nefopam. Indeed, ondansetron is likely to reduce the incidence of vomiting induced by nefopam administration significantly, even though it has very little effect on the incidence of nausea [@B27].

In conclusion, the present study provides the first evidence that administration of nefopam in PCIA can provide efficacious and safe postoperative analgesia to patients after minimally invasive surgery. Moreover, comparing with using nefopam alone, nefopam plus ondansetron can reduce gastrointestinal adverse events without compromising analgesic efficacy.

![Pain intensity scores during the postoperative 24 hours. VAS: visual analog scale; 0 hr: the 0th hour after surgery; 6 hr: the 6th hour after surgery; 12 hr: the 12th hour after surgery; 24 hr: the 24th hour after surgery.](ijmsv10p1790g001){#F1}

###### 

Demographic Characteristics and Perioperative Data

                                                                          Group N (n=115)   Group O (n=115)
  ----------------------------------------------------------------------- ----------------- -----------------
  Age (yr)                                                                49 ± 9            53 ± 10
  Weight (kg)                                                             63.3 ± 9.4        67.8 ± 10.1
  Gender (M/F)                                                            64/51             73/42
  ASA I/II                                                                93/22             102/13
  Duration of surgery (min)                                               78 ± 23           71 ± 17
  Starting time of PCIA (min)                                             28 ± 17           24 ± 20
  Baseline pain intensity (VAS scores at postoperative 0 hour), *n* (%)                     
  Slight pain (10 - 30 mm)                                                26 (22.6%)        21 (18.3%)
  Moderate pain (40 - 60 mm)                                              82 (71.3%)        89 (77.4%)
  Severe pain (70 - 100 mm)                                               7 (6.1%)          5 (4.3%)

ASA: American Society of Anaesthesiologists physical status; PCIA: patient-controlled intravenous analgesia; VAS: visual analog scale.

Data are presented as mean ± SD, number or number (percent).

No statistically significant between-group differences (*P* ≥ 0.05).

###### 

SPID~24hr~ by VAS scores and the consumption of analgesic during the postoperative 24 hours

                                                                  Group N (n=115)   Group O (n=115)
  --------------------------------------------------------------- ----------------- -----------------
  SPID~24hr~ (mm)                                                 95.6 ± 57.4       109.3 ± 64.1
  95% CI of the SPID~24hr~ difference                             -14.28, 24.32     
  consumption of nefopam during the postoperative 24 hours (mg)   98 ± 12.4         104 ± 17.6

SPID~24hr~: the sum of pain intensity difference over 24 hours postoperatively; VAS: visual analog scale.

Data are presented as mean ± SD.

###### 

Incidence of adverse events during the postoperative 24 hours

                                         Group N (n=115)   Group O (n=115)
  -------------------------------------- ----------------- -----------------
  Nausea, *n* (%)                        34 (29.6%)        38 (33%)
  Vomitting, *n* (%)                     18 (15.7%)\*      4 (3.5%)
  Need for rescue antiemetics, *n* (%)   14 (12.2%)\*      3 (2.6%)
  Respiratory depression, *n* (%)        0                 0

Data are presented as number (percent).

\* *P* \< 0.05 compared with the Group O.

[^1]: \* These authors contributed equally to this work.

[^2]: Competing Interests: The authors have declared that no competing interest exists.
